FOCUSED ON THE DEVELOPMENT OF TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF :
Worsening heart failure
Hyponatremic acute heart failure
Worsening heart failure
Worsening heart failure
Worsening heart failure
Biology
CRF2 (Corticotropin-releasing factor receptor 2) is a plasma membrane receptor widely expressed in the cardiovascular, renal and metabolic systems.
In proof of concept studies in heart failure patients and in preclinical heart failure models, CRF2 agonists :
- Improve cardiac function and reduce pulmonary congestion
- Promote diuresis/natriuresis on top of standard of care without triggering a neurohumoral response
In right heart failure patients or models, CRF2 agonists:
- Reduce the left ventricular filling pressure
- Improve the right cardiac function and pulmonary arterial resistance
- Improve the cardiac remodeling
In sarcopenia preclinical models, CRF2 agonists :
- Increase the skeletal muscle mass
- Improve skeletal muscle function
In obesity preclinical models, CRF2 agonists :
- reduce body weight and % of fat mass
- preserve the lean mass
CRF2
Strategy
Endogenous ligands for CRF2 (urocortin 2 or stresscopin) have a very short half-life which makes them unsuitable for sub-chronic administration. Our strategy is to develop two potent, long acting and selective CRF2 agonists, one suitable for once daily subcutaneous administration for the treatment of worsening heart failure, and a second for a once monthly administration for the treatment of right heart failure and other indications such as obesity or sarcopenia.
